Subtitle: Market Intelligence, Clinical Progress, and High-Purity Reagents for Neuropathic Pain & Epilepsy Development.
TarMart Solution Ecosystem & Related Targets
"Comprehensive reagent toolkit for CACNA1H drug discovery. Select your modality below:"
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | CACNA1H Extracellular Loop Recombinant Protein High purity (>95%), Endotoxin controlled. Sequence Verified. Ideal for immunization and antibody screening. |
View CACNA1H Products |
| Gene Delivery | CACNA1H Promise-ORF / Lentivirus Full-length ORF for stable cell line construction. Optimized for high-expression patch-clamp and FLIPR assays. |
View CACNA1H Products |
| Benchmark Ab | Anti-CACNA1H Recombinant Antibody Recombinant positive control for flow cytometry and functional blocking assays. |
View CACNA1H Products |
| Validator | CACNA1H siRNA Set For knockdown verification and target specificity validation in cell-based assays. |
View CACNA1H Products |
| Related Target A | CACNA1G T-type calcium channel subfamily member (Cav3.1). Critical for off-target selectivity screening to prevent motor/cognitive side effects. |
View CACNA1G Products |
| Related Target B | CACNA1I T-type calcium channel subfamily member (Cav3.3). Essential panel component for comprehensive T-type selectivity profiling. |
View CACNA1I Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Multi-pass membrane conformation loss | Lentivirus-mediated stable cell line construction preserves native 24-transmembrane folded structure. |
| Subfamily cross-reactivity (Cav3.1/Cav3.3) | Homolog panel proteins (CACNA1G, CACNA1I) strictly verified by mass spectrometry for counter-screening. |
| Lack of Controls | Sequence-verified clinical benchmark antibodies and positive reference controls included. |
| False Positives in Small Molecule Screening | Validated siRNA sets included for functional knockdown and target-specific rescue verification. |
Live CACNA1H R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for CACNA1H (Cav3.2) therapeutics is intensifying, with major players shifting focus from traditional non-selective calcium channel blockers to highly selective small molecule modulators and state-dependent inhibitors. As first-generation therapies reach late-stage clinical trials for chronic pain and epilepsy, the next wave of R&D is targeting peripheral nociception pathways to avoid central nervous system toxicities.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule (State-dependent) | Praxis Precision Medicines, Jazz Pharmaceuticals | Essential Tremor, Neuropathic Pain, Epilepsy | High-throughput Screening (Need Lentivirus for Stable Cell Line expression) |
| Monoclonal Antibody | Academic Institutions, Innovative Biotechs | Peripheral Neuropathy, Inflammatory Pain | Epitope Mapping (Need High-purity Extracellular Loop Recombinant Proteins) |
| RNA Therapeutics | Gene Therapy Developers | Rare Channelopathies, Severe Pain | Knockdown Validation (Need Sequence-verified siRNA Sets) |